REYKJAVIK, Iceland, January 21 deCODE geneticsehf today emerged as a newly financed, private company focused on advancingthe science of human genetics and its application to products and servicesthat improve human health. The new company will be building on the scientificleadership in genetics it developed over more than a decade as a subsidiaryof deCODE genetics, Inc. deCODE ehf was this week purchased from its formerparent company by Saga Investments LLC, a consortium that includes PolarisVentures and ARCH Venture Partners, two leading life science investors.deCODE will continue all of its operations and product lines in this field,including its deCODE diagnostics disease risk tests; deCODEme(TM) personalgenome scans; and contract service offerings including genotyping, sequencingand data analysis. Going forward, deCODE will concentrate on translating itsscience into medically and commercially important products and services. Thecompany will be led by a two-man executive committee comprised of Earl "Duke"Collier, previously an executive vice president at Genzyme Corp.,who willserve as CEO, and Kari Stefansson, who will serve as executive chairman andpresident of research.
deCODE operates the most productive human gene discovery engine in theworld. It is driven by genetic and medical data from 500,000 participantsfrom around the globe taking part in its gene discovery work; comprehensivegenealogies linking the 140,000 Icelandic participants; a major CLIA- andCAP-certified genotyping and sequencing facility; and statistical andinformatics tools for mining large datasets, for maximizing the informationderived from genotyping and sequencing data, and for visualizing genetic anddisease data in research, in the clinic, and for subscribers to its genomescans.
"deCODE has led the world in discovering variants in the sequence of thehuman genome that affect the risk of common diseases. Our resources andexpertise have also enabled us to develop the leading analytical tools in thefield, and we are putting all of this to work to provide unique value forpatients, physicians and researchers. As we enter the era of sequencingentire genomes, we believe our ability to make sense of ever larger amountsof data will continue to keep us in the lead in discovery. And with our nowsolid financial backing and the splendid addition of Duke Collier to ourmanagement, we will be taking a lead in the translation of our science intopowerful products and services." said Kari Stefansson.
"I am pleased to be joining Kari and the outstanding scientific team atdeCODE," said Duke Collier. "deCODE combines world class science devoted tohuman genetics, unmatched access to genetic data, and a powerful set of toolsfor managing and analyzing this data. SNP genotyping, and now genomicsequencing, is taking human genetics into an ever expanding world ofresearch, discovery and translation. With its scientific skill and industrialscale analytical capacity, deCODE will be an invaluable partner toinvestigators, labs and companies working at the highest levels ofsophistication in this exciting field. I am thrilled by the challenge and theopportunity."
Headquartered in Reykjavik, Iceland, deCODE is a global leader inanalyzing and understanding the human genome. Using its unique expertise andpopulation resources, deCODE has discovered key genetic risk factors fordozens of common diseases ranging from cardiovascular disease to cancer.deCODE employs its capabilities to develop DNA-based tests and personalgenome scans to better understand individual risk and empower prevention. Italso licenses its tests, intellectual property and analytical tools topartners, and provides comprehensive genotyping, sequencing and data analysisservices to companies and research institutions around the globe. Through itsCLIA- and CAP-certified laboratory deCODE offers DNA-based tests for gaugingrisk and empowering prevention of common diseases, including deCODE T2(TM)for type 2 diabetes; deCODE AF(TM) for atrial fibrillation and stroke; deCODEMI(TM) for heart attack; deCODE ProstateCancer(TM) for prostate cancer;deCODE Glaucoma(TM) for a major type of glaucoma; and deCODE BreastCancer,for the common forms of breast cancer. Through its pioneering personal genomeanalysis service deCODEme(TM), deCODE enables individuals to betterunderstand their risk of dozens of common diseases and to learn about theirancestry and other traits. Visit us on the web at http://www.decode.com; athttp://www.decodediagnostics.com; at http://www.decodeme.com; and on our blogat http://www.decodeyou.com.
deCODE genetics is a private company headquartered in Reykjavik, Iceland.It is owned by Saga Investments LLC, an investment consortium includingPolaris Venture Partners and ARCH Venture Partners.Contacts: Edward Farmer +354-570-2819 firstname.lastname@example.org Gisli Arnason +354-570-1900 email@example.com Rick Leach +1-616-296-1816 firstname.lastname@example.org
SOURCE DeCODE Genetics Inc